Therapeutic Potential of Ex Vivo Expanded Endothelial Progenitor Cells for Myocardial Ischemia

By A. Kawamoto, H. Gwon, H. Iwaguro, J. Yamaguchi, S. Uchida, H. Masuda, Marcy Silver, Hong Ma, M. Kearney, J. Isner and 1 more. Circulation, 2001

1,293 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 (2004, methodology): “We used endothelial progenitor cells (EPCs) in these studies because ischemia-induced neovascularization is essential for tissue regeneratio”
Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure (2003, methodology): “The following inclusion criteria were required for patient enrollment: (1) chronic coronary artery disease with reversible perfusion defect detectable by singlephoton emission computed tomography (SPECT); (2) left ventricular (LV) ejection fraction (EF) 40%; (3) ineligibility for percutaneous or sur”
Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. (2005, background): “Supplementary to the improvement of neovascularization, injection of EPC also significantly improved cardiac function in animal models [10,11].”
Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. (2004, background): “that infusion of EPCs results in their incorporation into neovasculature at the ischemic site and limitation of tissue damage in animal models (3).”